Vol 55, No 6 (2021)
Letter to the Editors
Published online: 2021-10-27

open access

Page views 6670
Article views/downloads 835
Get Citation

Connect on Social Media

Connect on Social Media

D-penicillamine-induced lupus erythematosus as an adverse reaction of treatment of Wilson’s Disease

Agnieszka Jadwiga Antos1, Tomasz Litwin1, Adam Przybyłkowski2, Marta Skowrońska1, Iwona Kurkowska-Jastrzębska1, Anna Członkowska1
Pubmed: 34704604
Neurol Neurochir Pol 2021;55(6):595-597.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Członkowska A, Litwin T, Dusek P, et al. Wilson disease. Nat Rev Dis Primers. 2018; 4(1): 21.
  2. Antos A, Litwin T, Skowrońska M, et al. Pitfalls in diagnosing Wilson's Disease by genetic testing alone: the case of a 47-year-old woman with two pathogenic variants of the ATP7B gene. Neurol Neurochir Pol. 2020; 54(5): 478–480.
  3. Litwin T, Czlonkowska A, Socha P. Oral chelator treatment of Wilson Disease: d-penicillamine. In: Litwin T, Czlonkowska A, Socha P. ed. Clinical and translational perspectives on Wilson disease. Academic Press, Cambridge 2019: 357–364.
  4. Antonov D, Kazandjieva J, Etugov D, et al. Drug-induced lupus erythematosus. Clin Dermatol. 2004; 22(2): 157–166.
  5. Solhjoo M, Bansal P, Goyal A, et al. Drug-induced lupus erythematosus. StatPearls Publishing, Treasure Island 2021. https://www.ncbi.nlm.nih.gov/books/NBK441889 (29.07.2021).